<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230224057514N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-15</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Vitamin D in knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of platelet-enriched plasma along with vitamin D and platelet-enriched plasma without vitamin D in improving function and reducing pain in knee osteoarthritis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69051</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The block randomization method will be used for randomization. The length of the block is considered to be 4 for each of the treatment groups, that is, each block will include two people from the intervention group and two people from the comparison group. We denote the intervention group with the letter A and the people of the comparison group with the letter B. In this case, we will have 6 combinations of four in the form of (AA,BB), (AB,BA), (BA,BA), (BA,BA), (BB,AA), and (AB,BA). In the Excel software, these blocks are sorted from 1 to 6, and then with the help of this software, one of these blocks is randomly selected, and based on the sequence of letters A and B in the selected block, the eligible people refer to and Admissions will be assigned to treatment or comparison groups. This random process of selecting blocks and assigning people to intervention and comparison groups will continue until the desired sample size is reached, Blinding description: This study is designed in a triple-blind manner, so that the injector, the outcome assessor and the patient are not aware of the status of assigning people to the study groups. For the study subjects, before the random allocation, it is explained how the work process is and they may receive one of the two treatments randomly, and the drug used for the subjects is not known in advance. On the other hand, the injection of vitamin D and PRP in the intervention group is done in the same syringe as in the PRP only (comparison) group, so the patient will be unaware of which group he is in. The injecting person will also be unaware of the patients' belonging to the treatment groups, because the sampling and preparation of the injectable substance is done by another person, and after entering the study, people will be anonymously and with a code to the injecting agent. they are introduced. Also, the outcome evaluator will not know about the status of assigning people to the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Osteoarthritis of the knee joint.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, first, 20 ml of blood is taken from the patient and centrifuged for 15 minutes at 1600 rpm to separate the erythrocytes and then 7 minutes at 2800 rpm to concentrate the platelets, then 300,000 IU of vitamin D solution is added to it. 8 minutes before the injection, the skin of the injection site is anesthetized by injecting 2 ml of 1% lidocaine. 3 ml of the prepared solution is drawn into a syringe and injected into the knee joint. Intervention 2: Control group: All the above cases are also done for the comparison group, with the difference that in this group, the injected solution does not contain vitamin D.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Participants Data File, Study Protocol, Statistical Analysis Map, Consent Form and Clinical Study Report will be shared after completion of the study.Participants' data file is not identifiable by others

When:
The data of this study will be shared one month after printing the results and will be available for one year

To whom:
All researchers interested in research in this study can access data

Conditions:
1.People who request access to data must be committed to the intellectual rights of researchers.
2.Avoid data manipulation and consequently unrealistic analysis.

Where to obtain:
Researchers interested in access to data in this study can refer to the clinical research unit of Shahid Madani Hospital

How to obtain:
Researchers interested in access to data in this study can refer to the Shahid Madani Hospital Clinical Research Development Unit and submit their official request to access data. After making the necessary reviews and obligations, the data will be made available to them.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amirhossein Haghshenas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Madani hospital, Mahan blvd, Jahanshahr, Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143746693</zip>
        <telephone>+98 26 3442 7001</telephone>
        <email>face.off1990amir@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amirhossein Haghshenas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Madani hospital, Mahan blvd, Jahahnshahr, Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143746693</zip>
        <telephone>+98 26 3442 7001</telephone>
        <email>face.off1990amir@gmail.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having informed consent
Suffering from osteoarthritis based on the criteria of the American Rheumatology Association
Receiving non-invasive treatments for at least 6 months
Having a body mass index below 30</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of fracture or previous surgery on the studied joint
Diagnosis of secondary osteoarthritis
History of drug sensitivity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, first, 20 ml of blood is taken from the patient and centrifuged for 15 minutes at 1600 rpm to separate the erythrocytes and then 7 minutes at 2800 rpm to concentrate the platelets, then 300,000 IU of vitamin D solution is added to it. 8 minutes before the injection, the skin of the injection site is anesthetized by injecting 2 ml of 1% lidocaine. 3 ml of the prepared solution is drawn into a syringe and injected into the knee joint.</i_keyword>
      <i_keyword>Control group: All the above cases are also done for the comparison group, with the difference that in this group, the injected solution does not contain vitamin D</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee joint pain. Timepoint: Pain measurement will be done at the beginning of the study, the first week, the first month, the second month and the sixth month after the treatment. Method of measurement: Vas score index.</prim_outcome>
      <prim_outcome>Functional status of the knee joint. Timepoint: The functional condition of the knee joint will be examined at the beginning of the study, the first week, the first month, the second month and the sixth month after the treatment. Method of measurement: WOMAC score index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-19</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>Vice President of Research and Technology of Alborz University of Medical Sciences, Safarian St, Golshahr, Karaj Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
